Assessment of circularized E7 RNA, GLUT1, and PD-L1 in anal squamous cell carcinoma

Anal squamous cell carcinoma (ASCC) is a rare, potentially fatal malignancy primarily caused by high-risk human papillomaviruses (HPV). The prognostic implication of programmed death-ligand 1 (PD-L1) expression remains controversial, and glucose transporter 1 (GLUT1) expression has never been examined in ASCC. Covalently closed circular RNAs have recently been shown to be widespread in cancers and are proposed to be biomarkers. We discovered HPV16 expresses a circular E7 RNA (circE7) which has not been assessed as a potential biomarker. A retrospective, translational case series at UT Southwestern was conducted to analyze PD-L1, GLUT1, HPV-ISH, and HPV circE7 in relation to the clinical features and overall survival of patients with ASCC. Twenty-two (22) subjects were included in the study. Improved overall survival was predicted by basaloid histology ( p = 0.013), PD-L1 expression ( p = 0.08), and HPV-ISH positivity ( p & 0.001), but not GLUT1 expression. High levels of circE7 by quantitative RT-PCR predicted improved overall survival in ASCC ( p = 0.023) and analysis of The Cancer Genome Atlas sequencing from HPV-positive head and neck cancer and cervical cancer suggested high circE7 marked improved survival in 875 subjects ( p = 0.074). While our study suggests that circE7 levels correlate with improved survival in ASCC, larger, prospective studies are necessary to confirm the potential role of circE7 as a biomarker.

[1]  Xiaowei Zhan,et al.  Transforming activity of an oncoprotein-encoding circular RNA from human papillomavirus , 2019, Nature Communications.

[2]  S. Dhanasekaran,et al.  The Landscape of Circular RNA in Cancer , 2019, Cell.

[3]  Alain Bergeron,et al.  Widespread and Functional RNA Circularization in Localized Prostate Cancer , 2019, Cell.

[4]  Zhenguo Shi,et al.  CircPCNXL2 sponges miR-153 to promote the proliferation and invasion of renal cancer cells through upregulating ZEB2 , 2018, Cell cycle.

[5]  E. Tartour,et al.  Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and RNA in situ hybridization) to evaluate a human papillomavirus infection in head and neck cancers: a cohort of 348 French squamous cell carcinomas. , 2018, Human pathology.

[6]  R. Deberardinis,et al.  Differential Glucose Requirement in Skin Homeostasis and Injury Identifies a Therapeutic Target for Psoriasis , 2018, Nature Medicine.

[7]  Shenglin Huang,et al.  Circular RNA: An emerging non-coding RNA as a regulator and biomarker in cancer. , 2018, Cancer letters.

[8]  C. Rödel,et al.  Anal squamous cell carcinoma - State of the art management and future perspectives. , 2018, Cancer treatment reviews.

[9]  T. Robinson,et al.  A National-Level Validation of the New American Joint Committee on Cancer 8th Edition Subclassification of Stage IIA and B Anal Squamous Cell Cancer , 2018, Annals of Surgical Oncology.

[10]  C. Rödel,et al.  Prognostic impact of RITA expression in patients with anal squamous cell carcinoma treated with chemoradiotherapy. , 2017, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  E. Siegel,et al.  Programmed Cell Death-Ligand 1 (PD-L1) Expression in Anal Cancer , 2016, American journal of clinical oncology.

[12]  L. Bullinger,et al.  Circular RNAs in Cancer. , 2018, Advances in experimental medicine and biology.

[13]  C. Rödel,et al.  The immune microenvironment and HPV in anal cancer: Rationale to complement chemoradiation with immunotherapy. , 2017, Biochimica et biophysica acta. Reviews on cancer.

[14]  K. Emancipator,et al.  Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  Yu Zhou,et al.  The prognostic value of GLUT1 in cancers: a systematic review and meta-analysis , 2017, Oncotarget.

[16]  Binbin Xie,et al.  Glucose transporter GLUT1 expression and clinical outcome in solid tumors: a systematic review and meta-analysis , 2017, Oncotarget.

[17]  C. Rödel,et al.  Human papilloma virus load and PD-1/PD-L1, CD8+ and FOXP3 in anal cancer patients treated with chemoradiotherapy: Rationale for immunotherapy , 2017, Oncoimmunology.

[18]  J. Taube,et al.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy , 2016, Nature Reviews Cancer.

[19]  W. Ge,et al.  HPV 16 E7 inhibits OSCC cell proliferation, invasion, and metastasis by upregulating the expression of miR-20a , 2016, Tumor Biology.

[20]  R. Wirtz,et al.  Human papillomavirus DNA load and p16INK4a expression predict for local control in patients with anal squamous cell carcinoma treated with chemoradiotherapy , 2015, International journal of cancer.

[21]  M. Poljak,et al.  Human papillomavirus DNA prevalence and type distribution in anal carcinomas worldwide , 2015, International journal of cancer.

[22]  S. Steele,et al.  Anal squamous cell carcinoma: an evolution in disease and management. , 2014, World journal of gastroenterology.

[23]  V. Guttikonda,et al.  Glut-1 as a prognostic biomarker in oral squamous cell carcinoma , 2014, Journal of oral and maxillofacial pathology : JOMFP.

[24]  L. Mazzucchelli,et al.  EGFR, KRAS, BRAF, and PIK3CA characterization in squamous cell anal cancer. , 2014, Histology and histopathology.

[25]  R. Kimple,et al.  Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck. , 2014, International journal of radiation oncology, biology, physics.

[26]  J. Feliu,et al.  Phase 1 study of cetuximab in combination with 5‐fluorouracil, cisplatin, and radiotherapy in patients with locally advanced anal canal carcinoma , 2014, Cancer.

[27]  J. Pignon,et al.  Unexpected toxicity of cetuximab combined with conventional chemoradiotherapy in patients with locally advanced anal cancer: results of the UNICANCER ACCORD 16 phase II trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[28]  J. Ledermann,et al.  Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial. , 2013, The Lancet. Oncology.

[29]  L. Szablewski Expression of glucose transporters in cancers. , 2013, Biochimica et biophysica acta.

[30]  Alison P. Klein,et al.  Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape , 2012, Science Translational Medicine.

[31]  Cary A Moody,et al.  Human papillomavirus oncoproteins: pathways to transformation , 2010, Nature Reviews Cancer.

[32]  K. Ang,et al.  Human papillomavirus and survival of patients with oropharyngeal cancer. , 2010, The New England journal of medicine.

[33]  D. Sabatini,et al.  Cancer Cell Metabolism: Warburg and Beyond , 2008, Cell.

[34]  Charles R. Thomas,et al.  Squamous cell carcinoma of the anal canal. , 2005, Surgical oncology.

[35]  A. Allal,et al.  Differential expression of anti-apoptotic protein Bcl-2 in keratinizing versus non-keratinizing squamous cell carcinoma of the anus , 2005, International Journal of Colorectal Disease.

[36]  J. Hilden,et al.  Anal cancer subtype reproducibility study , 2000, Virchows Archiv.

[37]  H. Adami,et al.  Variants of squamous cell carcinoma of the anal canal and perianal skin and their relation to human papillomaviruses. , 1999, Cancer research.

[38]  R. Coates,et al.  Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. , 1987, The New England journal of medicine.